Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 3/20 | 0.52 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.50 |
| ▸ | MME | P08473 | 7/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.34 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7070376 | 1.00 | TGFBR1 (0.52) | TGFBR1OR51E2MMEACECA2 | |
| SCHEMBL6253538 | 0.89 | ACE (0.49) | TGFBR1OR51E2MMEACECA2 | |
| SCHEMBL2633846 | 0.87 | ACE (0.47) | TGFBR1OR51E2MMEACECA2 | |
| SCHEMBL28806122 | 0.85 | OR51E2 (0.44) | TGFBR1OR51E2MMEACEFOLH1 | |
| SCHEMBL8491732 | 0.85 | OR51E2 (0.44) | TGFBR1OR51E2MMEACEFOLH1 | |
| SCHEMBL4363673 | 0.85 | ACE (0.58) | TGFBR1OR51E2MMEACECA2 | |
| SCHEMBL321602 | 0.85 | ACE (0.58) | TGFBR1OR51E2MMEACECA2 | |
| SCHEMBL29837094 | 0.85 | OR51E2 (0.44) | TGFBR1OR51E2MMEACEFOLH1 | |
| SCHEMBL8216927 | 0.85 | ACE (0.58) | TGFBR1OR51E2MMEACECA2 | |
| SCHEMBL8491734 | 0.85 | OR51E2 (0.44) | TGFBR1OR51E2MMEACEFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060018864-A1 | Cosmetic preparation containing glycerylamino acid derivative | SEIWA KASEI COMPANY, LIMITED (JP) | 2006-01-26 | — | — | US | disclosed |
| EP-1584320-A1 | COSMETIC PREPARATION CONTAINING GLYCERYLAMINO ACID DERIVATIVE | Seiwa Kasei Company, Limited (JP) | 2005-10-12 | — | — | EP | disclosed |
| US-5998362-A | OLIGOPEPTIDES, HAVING AMINO ACID SEQUENCES THAT ARE SELECTIVELY PROTEOLYTICALLY CLEAVED BY FREE PROSTATE SPECIFIC ANTIGEN (PSA), HYDROPHILIC OLIGOPEPTIDE BLOCKING GROUPS | MERCK & CO., INC. (US) | 1999-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060018864-A1 | Cosmetic preparation containing glycerylamino acid derivative | GLA, GPKOW, CUTA | TGFBR1 4512/4885OR51E2 2335/4885MME 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.